This is mainly a sequencing-risk equity, not a demand-risk equity. The biggest hazards are
Neutron proving late or imperfectly, financing or approval friction around Iridium, and the possibility that vertical integration raises complexity faster than it raises recurring cash generation. The business is strategically real; the question is whether it can scale into its valuation without a long detour through
dilution, leverage, or multiple compression.